| |
| |
|
| Insider
Information: |
Hallal David |
| Relationship: |
Director |
| City: |
Cheshire |
| State: |
CT |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
2,920,473 |
|
|
Indirect Shares
|
17,647,006 |
|
|
| Direct
Value |
$38,917,709 |
|
|
|
Indirect Value
|
$33,839,013 |
|
|
| Total
Shares |
20,567,479 |
|
|
| Total
Value |
$72,756,722 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
3
|
|
Stock
price went up :
|
0
|
1
|
| Stock
price went down : |
0
|
2
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -113.4%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Alexion Pharmaceuticals Inc |
ALXN |
CEO, Director |
2016-08-08 |
189,266 |
2014-12-18 |
113,122 |
Premium* |
|
|
Scholar Rock Holding Corp |
SRRK |
Director |
2019-09-18 |
290,595 |
2019-09-18 |
0 |
Premium* |
|
|
Allovir Inc |
ALVR |
|
2024-06-06 |
2,143,662 |
2024-06-06 |
17,533,884 |
Premium* |
|
|
Seer, Inc. |
SEER |
Director |
2023-06-14 |
296,950 |
|
0 |
Premium* |
|
|
Iteos Therapeutics, Inc. |
ITOS |
Director |
2022-06-09 |
0 |
2021-12-20 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
128 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 6
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ALVR |
Allovir Inc |
Chief Executive OfficerOfficer |
• • • |
2020-07-29 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
964,388 |
|
- |
|
| ALVR |
Allovir Inc |
Chief Executive OfficerOfficer |
• • • |
2020-07-29 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,083,666 |
|
- |
|
| ALVR |
Allovir Inc |
Chief Executive Officer |
• • • |
2020-08-03 |
4 |
A |
$0.00 |
$0 |
I/I |
14,315,700 |
738,153 |
0 |
- |
|
| ALVR |
Allovir Inc |
Chief Executive Officer |
• • • |
2021-01-21 |
4 |
A |
$0.00 |
$0 |
D/D |
147,000 |
2,230,666 |
0 |
- |
|
| ALVR |
Allovir Inc |
Director |
– • • |
2022-01-24 |
4 |
S |
$8.01 |
$136,889 |
D/D |
(17,100) |
2,213,566 |
0 |
% |
|
| ALVR |
Allovir Inc |
Director |
– • • |
2022-03-10 |
4 |
AS |
$7.55 |
$305,781 |
D/D |
(40,481) |
2,173,085 |
0 |
% |
|
| ALVR |
Allovir Inc |
Director |
– • • |
2022-03-11 |
4 |
AS |
$7.37 |
$186,068 |
D/D |
(25,244) |
2,147,841 |
0 |
% |
|
| ALVR |
Allovir Inc |
Director |
– • • |
2022-04-21 |
4 |
AS |
$5.87 |
$24,812 |
D/D |
(4,227) |
2,143,614 |
0 |
% |
|
| ALVR |
Allovir Inc |
Director |
– • • |
2022-06-03 |
4 |
AS |
$3.67 |
$241,106 |
D/D |
(65,725) |
2,077,889 |
0 |
% |
|
| ALVR |
Allovir Inc |
Director |
– • • |
2022-07-21 |
4 |
AS |
$5.33 |
$22,528 |
D/D |
(4,227) |
2,073,662 |
0 |
% |
|
| ALVR |
Allovir Inc |
Director |
– • • |
2022-07-28 |
4 |
A |
$4.61 |
$15,000,000 |
I/I |
3,253,796 |
16,674,766 |
0 |
- |
|
| ALVR |
Allovir Inc |
Director |
– • • |
2022-09-29 |
4 |
S |
$7.35 |
$2,940,920 |
I/I |
(400,000) |
720,965 |
0 |
% |
|
| ALVR |
Allovir Inc |
Director |
– • • |
2022-10-19 |
4 |
S |
$8.45 |
$5,070,000 |
I/I |
(600,000) |
138,153 |
0 |
% |
|
| ALVR |
Allovir Inc |
Director |
– • • |
2023-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
35,000 |
2,108,662 |
0 |
- |
|
| ALVR |
Allovir Inc |
|
– • • |
2024-06-06 |
4 |
A |
$0.00 |
$0 |
D/D |
35,000 |
2,143,662 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
SVP, Comm Opns, AmericasOffice |
• – – |
2009-02-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
12,230 |
|
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
Sr. VP Comm. Ops, Americas |
• – – |
2009-06-11 |
4 |
S |
$38.00 |
$136,420 |
D/D |
(3,590) |
19,910 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
Sr. VP Comm Ops, Americas |
• – – |
2009-06-19 |
4 |
S |
$38.47 |
$30,353 |
D/D |
(789) |
19,121 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
Sr. VP Comm Ops, Americas |
• – – |
2009-07-16 |
4 |
S |
$38.96 |
$9,272 |
D/D |
(238) |
18,883 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
Sr. VP Comm Ops, Americas |
• – – |
2009-07-27 |
4 |
S |
$43.00 |
$371,520 |
D/D |
(8,640) |
10,243 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
SVP Commercial Ops, Americas |
• – – |
2009-12-11 |
4 |
S |
$46.40 |
$464,000 |
D/D |
(10,000) |
10,243 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
SVP Commercial Ops, Americas |
• – – |
2009-12-11 |
4 |
OE |
$16.32 |
$163,200 |
D/D |
10,000 |
20,243 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
SVP Commercial Ops, Americas |
• – – |
2009-12-21 |
4 |
S |
$47.79 |
$43,776 |
D/D |
(916) |
9,327 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
SVP Commercial Ops, Americas |
• – – |
2010-01-11 |
4 |
S |
$47.78 |
$51,985 |
D/D |
(1,088) |
8,239 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
SVP Commercial Ops, Americas |
• – – |
2010-01-19 |
4 |
S |
$47.22 |
$10,719 |
D/D |
(227) |
8,012 |
0 |
- |
|
128 Records found
|
|
Page 1 of 6 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
